A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma
Figure 2
Depletion of Tregs by anti-CD25 mAb clone PC61 or anti-CD25 mAb clone 7D4. (a) Tregs infiltration in untreated glioma-bearing (control) mice. (b), (c) Tregs depletion in mice treated by systemic or combined injections of the anti-CD25 mAb PC61. (c), (e) Tregs depletion in mice treated by systemic or combined injections of the anti-CD25 mAb 7D4. Data are presented as the percentage average of positive cells and represent the mean of three independent experiments ().
